Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
58 hedge funds and large institutions have $16.5M invested in Asterias Biotherapeutics Inc. Series A in 2015 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 14 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 63 → 58 (-5)
14% less capital invested
Capital invested by funds: $19.3M → $16.5M (-$2.78M)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $121K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$500K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$464K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$342K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$280K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$230K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$894K |
| 2 |
Millennium Management
New York
|
-$617K |
| 3 |
Citigroup
New York
|
-$107K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$106K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$97K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
51
A.R.T. Advisors
New York
| – | -$88K | -19,216 | Closed |
|
|
HCM
52
Highbridge Capital Management
New York
| – | -$79K | -17,105 | Closed |
|
|
AIM
53
Allen Investment Management
New York
| – | -$71K | -15,524 | Closed |
|
|
DAM
54
Deltec Asset Management
New York
| – | -$69K | -15,000 | Closed |
|
55
Squarepoint
New York
| – | -$47K | -10,200 | Closed |
|
|
FNYS
56
First New York Securities
New York
| – | -$26.2K | -5,700 | Closed |
|
|
SO
57
STRS Ohio
Columbus,
Ohio
| – | -$15.2K | -3,300 | Closed |
|
58
Invesco
Atlanta,
Georgia
| – | -$6K | -1,239 | Closed |
|
|
GWM
59
Gupta Wealth Management
San Diego,
California
| – | -$1K | -166 | Closed |
|
AST Hedge Fund Activity: Q3 2015 in Review
58 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q3 2015, worth a combined $16.5M — down 14% from $19.3M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AST and 10 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 14 added.
The largest buyer was BlackRock Institutional Trust, adding an estimated $500K. The largest seller was Vanguard Group, cutting an estimated $894K.
- 58 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q3 2015, down from 63 in Q2 2015.
- Funds reported $16.5M of Asterias Biotherapeutics Inc. Series A stock for Q3 2015, down 14% quarter-over-quarter.
- 10 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q3 2015 and 14 closed out, a net change of -4 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q3 2015 was BlackRock Institutional Trust, an estimated $500K added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q3 2015 was Vanguard Group, an estimated $894K sold.
Based on aggregated 13F filings for Q3 2015.